33 results on '"Morita, Mitsunori"'
Search Results
2. A survey of carboplatin desensitization therapy in Japan: A multicenter retrospective study
3. Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
4. Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study
5. Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non–small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study
6. Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001)
7. Pseudoprogression in Previously Treated Patients with Non–Small Cell Lung Cancer Who Received Nivolumab Monotherapy
8. Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab
9. Retroperitoneal Metastasis from Lung Adenocarcinoma Mimics Retroperitoneal Fibrosis
10. Classification and regression tree for estimating predictive markers to detect T790M mutations after acquired resistance to first line EGFR-TKI: HOPE-002
11. Additional file 2 of Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study
12. Additional file 1 of Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study
13. Additional file 3 of Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study
14. Additional file 1 of Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab
15. MPO-ANCA Positive Granulomatosis with Polyangitis (Wegenerʼs) may be Equated to PR3-ANCA Positive Cases: Comparative Investigation of Clinical and Radiological Findings: OS124
16. Multimerization of restriction fragments by magnesium-mediated stable base pairing between overhangs: a cause of electrophoretic mobility shift
17. Prediction of patients with a tumor proportion score >50% who do not respond to first-line monotherapy with pembrolizumab
18. Prediction of patients with a tumor proportion score >50% who do not respond to first-line monotherapy with pembrolizumab
19. Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non–small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study
20. Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial
21. Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan
22. A Phase II Study of Cisplatin Plus Gemcitabine followed by Maintenance Gemcitabine for Advanced Squamous Non-Small-Cell Lung Cancer: Kyoto Thoracic Oncology Research Group 1302
23. Infective endocarditis presenting as diffuse alveolar hemorrhage: A case report
24. Additional file 1: Table S1. of Serum albumin level as a potential marker for deciding chemotherapy or best supportive care in elderly, advanced non-small cell lung cancer patients with poor performance status
25. Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study
26. Serum albumin level as a potential marker for deciding chemotherapy or best supportive care in elderly, advanced non-small cell lung cancer patients with poor performance status
27. P2.06-015 The NICE Salvage Study: A Phase II Trial of Weekly Nab-Paclitaxel in the Salvage Setting for Advanced Non-Small Cell Lung Cancer
28. Interstitial lung disease in clinically amyopathic dermatomyositis with and without anti-MDA-5 antibody: to lump or split?
29. Survey of carboplatin desensitization therapy: JCOG Gynecologic Cancer Study Group multicenter retrospective study.
30. Serum albumin level as a potential marker for deciding chemotherapy or best supportive care in elderly, advanced non-small cell lung cancer patients with poor performance status.
31. Successful Treatment of Fulminant Community-Acquired Pseudomonas aeruginosa Necrotizing Pneumonia in a Previously Healthy Young Man
32. Structural Property of DNA That Migrates Faster in Gel Electrophoresis, as Deduced by CD Spectroscopy
33. Retroperitoneal Metastasis from Lung Adenocarcinoma Mimics Retroperitoneal Fibrosis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.